We are live on ! Find out more
BVS icon

Bioventus

13.20 USD
+0.20
1.54%
At close Updated Sep 16, 4:00 PM EDT
1 day
1.54%
5 days
-2.37%
1 month
-4.9%
3 months
51.38%
6 months
48.82%
Year to date
83.08%
1 year
92.98%
5 years
-7.69%
10 years
-31.29%
 

About: Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

Employees: 950

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 70%
Neutral 20%
Negative 10%
Negative
Zacks Investment Research
23 days ago
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Negative
Zacks Investment Research
27 days ago
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
Positive
Zacks Investment Research
1 month ago
Is Bioventus (BVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Bioventus (BVS) Stock Undervalued Right Now?
Neutral
Seeking Alpha
1 month ago
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Positive
MarketBeat
1 month ago
Bioventus Q2 Earnings Call Highlights
Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.
Bioventus Q2 Earnings Call Highlights
Positive
Zacks Investment Research
1 month ago
Bioventus (BVS) Q2 Earnings Meet Estimates
Bioventus (BVS) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.21 per share a year ago.
Bioventus (BVS) Q2 Earnings Meet Estimates
Neutral
GlobeNewsWire
1 month ago
Bioventus Reports Second Quarter Financial Results
DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.
Bioventus Reports Second Quarter Financial Results
Positive
Zacks Investment Research
1 month ago
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth
Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth
Neutral
GlobeNewsWire
1 month ago
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026.
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
Positive
Zacks Investment Research
1 month ago
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
Price charts implemented using Lightweight Charts™